

# Peter F Hahn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6738015/publications.pdf>

Version: 2024-02-01

30  
papers

818  
citations

759233

12  
h-index

501196

28  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1565  
citing authors

#	ARTICLE	IF	CITATIONS
1	Virtual Unenhanced Images. Investigative Radiology, 2022, 57, 52-61.	6.2	14
2	Low keV portal venous phase as a surrogate for pancreatic phase in a pancreatic protocol dual-energy CT: feasibility, image quality, and lesion conspicuity. European Radiology, 2021, 31, 6898-6908.	4.5	10
3	Cross-sectional imaging findings of splenic infections: is differential diagnosis possible?. Abdominal Radiology, 2021, 46, 4828-4852.	2.1	7
4	Identifying the deceiver: the non-neoplastic mimickers of genital system neoplasms. Insights Into Imaging, 2021, 12, 95.	3.4	0
5	Imaging findings of infectious and inflammatory diseases of the urinary system mimicking neoplastic diseases. Abdominal Radiology, 2020, 45, 1110-1121.	2.1	1
6	Abdominal Imaging Findings in COVID-19: Preliminary Observations. Radiology, 2020, 297, E207-E215.	7.3	251
7	Non-neoplastic hepatopancreatobiliary lesions simulating malignancy: can we differentiate?. Insights Into Imaging, 2020, 11, 21.	3.4	2
8	Primary lymphomas of the intraabdominal solid organs and the gastrointestinal tract: spectrum of imaging findings with histopathological confirmation. Abdominal Radiology, 2019, 44, 2988-3005.	2.1	5
9	Aorta-Lesion-Attenuation-Difference (ALAD) on contrast-enhanced CT: a potential imaging biomarker for differentiating malignant from benign oncocytic neoplasms. Abdominal Radiology, 2017, 42, 1734-1743.	2.1	11
10	Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdominal Radiology, 2017, 42, 1141-1151.	2.1	52
11	Impact of low-energy CT imaging on selection of positive oral contrast media concentration. Abdominal Radiology, 2017, 42, 1298-1309.	2.1	6
12	Extranodal lymphomas of abdomen and pelvis: imaging findings and differential diagnosis. Abdominal Radiology, 2017, 42, 1096-1112.	2.1	14
13	Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial. Practical Radiation Oncology, 2016, 6, e9-e16.	2.1	9
14	Spleen volume on CT and the effect of abdominal trauma. Emergency Radiology, 2016, 23, 315-323.	1.8	12
15	Diffusion MRI of uterine and ovarian masses: identifying the benign lesions. Abdominal Radiology, 2016, 41, 2466-2475.	2.1	18
16	Distinguishing hemangiomas from metastases on liver MRI performed with gadoxetate disodium: Value of the extended washout sign. European Journal of Radiology, 2016, 85, 635-640.	2.6	6
17	Role of percutaneous abscess drainage in the management of young patients with Crohn disease. Pediatric Radiology, 2016, 46, 653-659.	2.0	16
18	Abscess due to perforated appendicitis: factors associated with successful percutaneous drainage. American Journal of Surgery, 2016, 212, 794-798.	1.8	13

#	ARTICLE	IF	CITATIONS
19	T2 relaxation time is related to liver fibrosis severity. Quantitative Imaging in Medicine and Surgery, 2016, 6, 103-114.	2.0	54
20	Quantitative study of prostate cancer using three dimensional fiber tractography. World Journal of Radiology, 2016, 8, 397.	1.1	6
21	Unusual Malignant Solid Neoplasms of the Kidney: Cross-Sectional Imaging Findings. Korean Journal of Radiology, 2015, 16, 853.	3.4	9
22	Iterative Reconstruction Techniques in Abdominopelvic CT: Technical Concepts and Clinical Implementation. American Journal of Roentgenology, 2015, 205, W19-W31.	2.2	59
23	Body MR Imaging: Artifacts, k-Space, and Solutions. Radiographics, 2015, 35, 1439-1460.	3.3	91
24	Image-Guided Ovarian Mass Biopsy: Efficacy and Safety. Journal of Vascular and Interventional Radiology, 2014, 25, 1922-1927.e1.	0.5	20
25	The clinical value of ferric ammonium citrate: A positive oral contrast agent for T1-weighted MR imaging of the upper abdomen. Journal of Magnetic Resonance Imaging, 2000, 12, 702-707.	3.4	14
26	Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: Phase II clinical trial data. Journal of Magnetic Resonance Imaging, 1999, 9, 291-294.	3.4	50
27	A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. Journal of Magnetic Resonance Imaging, 1999, 10, 15-24.	3.4	53
28	A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. Journal of Magnetic Resonance Imaging, 1999, 10, 15-24.	3.4	2
29	An aqueous gastrointestinal contrast agent for use in echo-planar MR imaging. Magnetic Resonance in Medicine, 1992, 25, 380-383.	3.0	12
30	Beyond splenomegaly: An image-based review of infectious and inflammatory diseases of the spleen. , 0, 24-29.		1